医学新闻与研究

In an open-label study of 10 blind patients receiving intravitreal AAV-ChrimsonR plus activating goggles, 6 achieved clinically meaningful FST gains, with one transient central retinal artery occlusion.

Difference-in-differences analysis of 77,000 person-years in the UKHLS links UC introduction to a 0.94-point SF-12 MCS decline and a 3.8 percentage-point rise in probable depression, with larger effects in bigger families.

In a randomized clinical trial, oral nicotinamide riboside showed no clinical benefit and was linked to modestly worse outcomes than placebo, arguing against disease-modifying use.

In the 360-patient TRIC-I-HF randomized trial (mean age 80), repair cut the 3-year composite risk by 60% with 5.9% major adverse events at 30 days.